Based on three phases of clinical trials, the overall efficacy rate of Covovax is estimated at around 89 per cent.
The Union government was responding to petition filed by parents of two women who allegedly died after receiving Covishield vaccines, as per reports.
Before Covaxin was approved for restricted emergency use in January 2021, the Subject Expert Committee reviewed the data on safety and immunogenicity of the vaccine and recommended for grant of permission for restricted use...
The government had, in April 2021, first exempted Covid-19 vaccines from 10 per cent customs duty
Refuting some media reports around the approvals for Covaxin, the vaccine maker said it condemns the "targeted narrative" against the vaccine put forth by a select few individuals and groups who have no expertise in vaccines...
Due to lack of product demand, Production stoppage of Covaxin- a two dose jab, was initiated by Bharat Biotech earlier this year, though the vaccine maker has established manufacturing to reach an annualised capacity of 1...
Neutralising antibody responses against the SARS-COV-2 virus and its variants of concern (VoC) are higher among Covishield recipients than those who took the indigenously made Covaxin, according to a multi-centre study.
Vaccine manufacturer Bharat Biotech is expecting to receive clearance for its intranasal covid-19 vaccine in the month of August.
Out of 88 post-vaccination SARS-CoV-2 breakthrough infections, 90.91 per cent were symptomatic cases and the remaining 9.09 per cent were...
NTAGI's Standing Technical Sub-Committee (STSC), however, couldn’t arrive at a decision on introducing Corbevax and Covaxin in the vaccination programme.
A study published in The Lancet Infectious Diseases medical journal shows that the vaccine 'induced higher neutralising antibody responses than those...
"The virus shedding and viral organ load were considerably reduced in both the two dose and three-dose immunised animals indicating the vaccine efficacy...
FDA had earlier implemented a temporary pause on Covaxin trials, following the WHO's observations on Covaxin manufacturing plants in India.
According to the EUA application submitted to DCGI, Biological E in a phase-3 placebo-controlled clinical study, based on the drug regulator's nod, has...
Although WHO maintained that the vaccine is effective and there is no safety concern, it has recommended that countries using the vaccine take action as...
Corbevax is currently being used to inoculate children against COVID-19 in the age group of 12 to 14 years.
The countrywide vaccination drive was rolled out on January 16 last year with healthcare workers getting inoculated in the first phase. Vaccination of...
Bharat Biotech's Covaxin cleared for 6-12 age group by drugs regulator DCGI, as per media reports
The company said it has received funding to initiate the Phase I and Phase II trials of an indigenous affordable Receptor-Binding Domain (RBD) based vaccine...
Vaccine majors SII and Bharat Biotech on Saturday said they have decided to cut the prices of the precaution dose of their respective COVID-19 vaccines to Rs...
The study by the ICMR and Covaxin manufacturer Bharat Biotech was conducted in January and the findings were published in the Journal of Travel Medicine on...
Citing good manufacturing practices deficiencies, the World Health Organization (WHO) on April 2 confirmed the suspension of supply of Covaxin
The WHO asked countries that have received the vaccine to take appropriate actions, according to the statement, but did not specify what the appropriate...
The WHO said the Bharat Biotech vaccine is effective and no safety concerns exist, but the suspension of production for export will result in the interruption...
Bharat Biotech Chairman and Managing Director Krishna Ella said, "We are proud to announce this partnership with BioFabri, where MTBVAC can become a global TB...
